Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs
Clinical Infectious Diseases · 06.01.2023 · 76 (1) · 165-171
DOI: 10.1093/cid/ciac180 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Infectious Diseases, online erschienen am 04.03.2022. Verfasst von Louis D Saravolatz und 2 weiteren Autor:innen. Beteiligte Einrichtung: Thomas Mackey Center for Infectious Diseases Research, Ascension St John Hospital, Grosse Pointe Woods, Michigan, USA. Hauptthemen laut MEDLINE: Antiviral Agents, COVID-19. Die Arbeit wurde bisher 280-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
At a crucial time with rapid spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant globally, the United States Food and Drug Administration has issued an emergency use authorization for 2 oral antivirals, molnupiravir (in persons aged ≥18 years) and nirmatrelvir-ritonavir (Paxlovid) (in persons aged ≥12 years weighing ≥40 kg), for the outpatient treatment of patients with mild to moderate coronavirus disease 2019 (COVID–19) who are at risk for progression. Molnupiravir is a nucleoside analogue, whereas nirmatrelvir is a SARS-CoV-2 main protease inhibitor, and ritonavir is a human immunodeficiency virus type 1 protease inhibitor. Drug interactions are a major concern for nirmatrelvir-ritonavir. Nirmatrelvir-ritonavir demonstrated a greater risk reduction in hospitalization and death than molnupiravir compared to placebo. Both drugs need to be started within 5 days of symptoms onset and given for 5 days’ duration. This article reviews the 2 oral COVID-19 antiviral drugs including the mechanisms of action, antiviral activity, pharmacokinetics, drug interactions, clinical experience including trials, adverse events, recommended indications, and formulary considerations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Thomas Mackey Center for Infectious Diseases Research, Ascension St John Hospital, Grosse Pointe Woods, Michigan, USA.
- Ascension-St John Hospital, Grosse Pointe Woods, Michigan, USA.
- Wayne State University School of Medicine, Detroit, Michigan, USA.
- Central Michigan University College of Medicine, Mt Pleasant, Michigan, USA.
- Ascension Rx Specialty Pharmacy, Grosse Pointe Woods, Michigan, USA.
Zitieren
APA
Saravolatz, L. D., Depcinski, S., & Sharma, M. (2023). Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs. Clinical Infectious Diseases, 76(1), 165-171. https://doi.org/10.1093/cid/ciac180
Vancouver
Saravolatz LD, Depcinski S, Sharma M. Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs. Clinical Infectious Diseases. 2023;76(1):165-171. doi:10.1093/cid/ciac180
BibTeX
@article{Saravolatz2023,
author = {Saravolatz, Louis D and Depcinski, Shawn and Sharma, Mamta},
title = {Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs},
journal = {Clinical Infectious Diseases},
year = {2023},
volume = {76},
number = {1},
pages = {165--171},
doi = {10.1093/cid/ciac180}
}
EUVIMED